#dihexa Dihexa Oral Capsules for Memory & Cognition Dihexa | Research Scientific Ltd

ChEMBL v34 compound record for TIRZEPATIDE (CHEMBL4297839): max_phase 4 (approved), first_approval 2022, parenteral, GIP receptor agonist, first-in-class, black-box warning flag

Cagrilintide dosing figures describe research settings with no approved label, and tirzepatides label regimen is cited for interpretation only, not as guidance

Despite these potential benefits, its crucial to remember that research is still emerging, and the FDA has not approved BPC-157 for any medical use

Its a repair and recovery peptide and is probably being used in some orthopedic practices, where its injected into injuries and joints that have failed to recover from complex injuries or surgeries, she says